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Abstract
Previous reports have questioned the safety of multiple doses of acetaminophen administered to ill children. Acetaminophen protein adducts (adducts)
are a biomarker of acetaminophen-induced liver injury and reflect the oxidative metabolism of acetaminophen, a known mechanism in acetaminophen
toxicity. In this prospective observational study, we analyzed adduct concentrations in 1034 blood samples obtained from 181 hospitalized children (1
to 18 years inclusive) who received 2 or more doses of acetaminophen. Linear regression analysis showed that serum adduct concentrations increased
as a function of the cumulative acetaminophen dose, which could be attributed, in part, to a long half-life of adducts (2.17 ± 1.04 days [mean ± standard
deviation]) in children. However, few patients (2%) were found to have adduct concentrations higher than 1.0 nmol/mL, a previously identified toxicity
cut point for the diagnosis of acetaminophen-induced liver injury in patients with alanine aminotransferase values exceeding 1000 IU/L. A small cohort
of patients with suspected infection was noted to show higher adduct concentrations. In addition, adduct concentrations showed a stronger correlation
with cumulative acetaminophen doses in adolescents compared with children (R2 = 0.41 vs 0.26). No other covariates (body weight, body mass index
z score, sex, race, or surgery) remarkably correlated with adduct elevation. In summary, low levels of adducts can be detected in hospitalized children
receiving multiple doses of acetaminophen, and adduct levels correlate with cumulative acetaminophen dose.
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Pain and fever are symptoms commonly encountered
in childhood, and acetaminophen (APAP) remains a
drug of choice for treatment in this population. APAP
is generally considered safe when used on an as-needed
basis at doses recommended by the manufacturer.1
Supratherapeutic doses of APAP, including those associated with intentional overdose, may cause severe
liver injury in some cases.2 Notably, some reports have
questioned the safety of APAP when administered at
the upper end of recommended doses over a multipleday period.3,4 A study published by Watkins et al
reported that more than 30% of adults administered
APAP 4 g/day for 4 days experienced elevations in
alanine aminotransferase (ALT) exceeding 3 times the
upper limit of normal,5 whereas a later study found
only mild or modest ALT elevations with prolonged
APAP administration.6 In children, liver injury secondary to repeated dosing of APAP is thought to be
rare but has been observed in several case reports.7–10
To date, development of occult toxicity in children
receiving APAP over multiday periods has not been
extensively evaluated, and it remains to be clarified
whether repeated doses of APAP increase the risk
of liver injury in children.11 Some clinical conditions

such as glutathione depletion, which may occur with
inadequate nutrient intake, may further increase the
risk of hepatotoxicity.12 As safety data on the long-term
use of APAP in children are lacking, more research is
needed to address this question.
APAP is primarily metabolized by phase II
metabolic enzymes through glucuronidation and
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sulfation in the liver.13 After the administration of a
therapeutic dose, phase I enzymes (cytochromes P450
[CYP] 2E1,14 2A6,15 and 2D616 ) contribute to around
5% of APAP metabolism.17 Oxidation of APAP forms
the toxic reactive metabolite N-acetyl-p-benzoquinone
imine (NAPQI), which is rapidly detoxified to APAPglutathione and then further converted to other
nontoxic metabolites. When high exposure to APAP
depletes hepatic glutathione, NAPQI covalently binds
to cysteine residues of proteins in hepatocytes to
form NAPQI-protein conjugates (APAP protein
adducts). APAP protein adducts are released from
hepatocytes as these cells rupture and can subsequently
be detectable in peripheral blood.18 Measurement of
adducts by high-performance liquid chromatography
with electrochemical detection (HPLC-EC) has shown
that adducts are both highly sensitive and specific
for APAP toxicity of ALT > 1000 IU/L, with a
proposed concentration of 1.0 nmol/mL, signaling
APAP-induced liver injury.19–21
The majority of previous research measuring APAP
protein adducts has focused on single acute overdose
or chronic APAP administration in adults.22–24 In this
prospective clinical study, we compared adduct measurements with APAP doses and biochemical measures
of liver injury in hospitalized children who received
multiple doses of APAP according to the standard
of care. We also examined the relationships between
clinical factors and adduct concentrations.

Methods
Study Design and Analytical Methods
This was a prospective, multicenter observational study
designed to evaluate biomarkers of APAP toxicity
in pediatric patients. Participants were enrolled with
informed permission/assent under a protocol reviewed
and approved by the institutional review boards at the
participating institutions (see acknowledgments for the
institution list). Written informed consent was obtained
from the participant’s parent/legal guardian before participation in the study. Hospitalized patients aged 118 years inclusive who were receiving or expected to
receive at least 2 doses of APAP during the hospitalization were eligible for participation. Patients with
a history of acute or chronic APAP overdose within
14 days and those with a known history of liver disease
or dysfunction were excluded.
Information collected on study participants included
demographic data along with APAP dosing (prior to
and during hospitalization), formulation, comedications, dosing interval, and the primary reason for the
hospitalization (Table 1). Blood samples were collected
for serum transaminase levels (aspartate aminotransferase [AST] and ALT) throughout the study and
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Table 1. Demographics and Clinical Characteristics of Patients
Demographic Characteristics

Patients, n (%)

Total
Age (years)
Infants (1 to <2)
Children (2 to <12)
Adolescents (12 to <18)
Sex
Male
Female
Race
African American
White
Asian
Othera
Surgery
Yes
No
Primary admission diagnosis
Cardiovascular
Fluids/electrolytes/nutrition
Gastrointestinal
Infection (suspected)b
Musculoskeletal
Neuropsychiatric
Oncologic
Respiratory/ENT
Trauma/burn
Otherc

181

Physiological characteristics
Body weight (kg)
Height (cm)
BMI z score

11 (6.1)
102 (56.4)
68 (37.6)
103 (56.9)
78 (43.1)
36 (20.0)
130 (72.4)
3 (1.7)
12 (6.6)
76 (42.0)
105 (58.0)
51 (28.2)
4 (2.2)
14 (7.7)
22 (12.2)
16 (8.8)
26 (14.4)
9 (5)
23 (12.7)
14 (7.7)
2 (1.1)
Mean ± SD
38.6 ± 30.3
126.6 ± 32.3
0.4 ± 1.8

a

More than 2 or unknown races.
Suspected infection included patients with either suspected or presumed
infection.
c
Missing information on primary admission diagnosis.
b

measured in local clinical laboratories of participating
institutions. For quantitation of APAP protein adducts,
blood samples were collected 8 and 24 hours after
the first dose of APAP (“first dose” was defined as
the first dose of APAP received once patients were
enrolled in the study, designated by signed consent);
subsequent samples were collected during predefined
study periods for patients continuing to receive APAP
as follows: days 2-6, days 7-14, days 15-21, and days
22-28. In addition, a blood sample was obtained
48 hours after discontinuation of APAP. Scavenged
blood samples (ie, samples no longer needed for clinical purposes) were also obtained for measurement of
APAP protein adducts. Blood samples were collected
in nonethylenediaminetetraacetic acid-containing vials
and centrifuged within 1 hour of blood draw. The
serum portion was removed and stored at -70°C until
the time of sample analysis. The samples were shipped
to a central, research laboratory and analyzed as
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Table 2. Summary of APAP Dosing and Sampling

Number of doses
Interval of dosing (hours)
Duration of treatment (days)
Dose (mg/kg)a
Number of samplings

Mean

Median

5%-95%
Percentilesb

Min-Max

7.8
11.0
3.7
12.3
5.7

5.0
6.3
1.8
12.1
4.0

2.0-19.0
3.1-34.9
1.0-14.0
5.6-17.6
1.0-14.0

2.0-76.0
2.0-42.0
1.0-26.3
3-35.1
1.0-26.0

a
Because it is a multiple-dose study,dose is defined as the mean dose (the total
dose divided by the total number of doses during the entire treatment) for an
individual patient, resulting in 181 (mean) doses calculated for 181 patients.
b
Percentile instead of standard deviation (SD) was presented because the
distributions of these variables were highly skewed.

singlets in batches within 6 months of sample collection. APAP protein adduct analysis was conducted
using a previously reported HPLC-EC method19 by
a single laboratory technician who was blinded to
the clinical histories of the study participants. The
lower limit of quantification (LLOQ) for the assay was
0.03 nmol/mL, with a coefficient of variation (CV)
of less than 15%. Body mass index (BMI) z scores
were calculated using the online calculator25 based on
patients’ body weight, height, sex, and age.
Exploratory Data Analysis
Patient demographics, clinical conditions, and APAP
dosing and sampling history were summarized (Tables 1
and 2). The clinical data were explored by graphical
analysis and Pearson correlation analysis to assess the
relationships among APAP doses, adduct concentrations, and transaminase levels. AST and ALT values
were linked to adduct measurements obtained within
48 hours of the adduct sample if adduct measurements
were not obtained at the same time as the hepatic
transaminase tests. The evaluated APAP doses included
unnormalized and body-weight-normalized mean and
cumulative doses. The cumulative dose was defined
as the total dose received before a blood sample was
obtained for adduct measurement for an individual
patient; the mean dose was calculated as the cumulative
dose divided by the number of doses that occurred
before a given adduct measurement. Where possible,
the calculated APAP doses included any reported doses
prior to hospitalization. The adduct concentrations and
APAP doses were evaluated both as untransformed and
log-transformed values.
Linear Regression Analysis
A standard parametric linear regression model was developed in R (version 3.4) to investigate the relationship
between the natural log-transformed cumulative dose
(mg/kg) and natural log-transformed adduct concentrations. Given the sparse and unbalanced sampling
scheme, for simplicity, only adduct concentrations ob-

tained within 48 hours of an APAP dose were included
in the regression analysis. The base bivariate linear
model consisted of an intercept term and a slope term
multiplied by the cumulative dose as the explanatory
variable for adduct concentrations. The goodness of
fit was assessed by diagnostic plots and coefficient
of determination (R2 ). A sensitivity analysis omitting
the patients dosed with APAP prior to admission was
performed to evaluate the impact of potential data
inaccuracy in the screening period. After the linear
relationship between the cumulative dose and adduct
concentrations was established, multiple regression
analysis and analysis of covariance (ANCOVA) were
performed to evaluate the correlation between various
covariates (age, body weight, BMI z score, sex, race,
surgery, and primary admission diagnosis) and adduct
concentrations. In addition, regression and correlation
analysis were performed on the patient data stratified
by categorical covariates (eg, age group, race, and primary admission diagnosis). For any cohort showing a
significant covariate effect, the distribution of sampling
points and formulations were analyzed to investigate
the potential confounding of unbalanced sampling
and/or prevailing formulation on the statistical analysis. The age groups were categorized as infants (1 to
<2 years), children (2 to <12 years), and adolescents
(12 to <18 years).
Individual Patient Analysis
Clinical data were screened for atypical patterns as well
as outliers. The patients displaying either a high adduct
level (ࣙ1.0 nmol/mL) or a high transaminase level
(ࣙ1000 IU/L) were examined on an individual basis
to investigate the possible causes for elevated adduct
concentrations or abnormal liver function.
Adduct Half-Life Analysis
The apparent adduct half-life was derived from the
terminal slope of the natural log-transformed adduct
concentrations when sufficient (n ࣙ 3) sampling points
after the most recent APAP dose were available. Those
sampling points included adduct measurements both
within and beyond 48 hours post-APAP administration. The R package PKNCA26 package was used to
compute the terminal slope (λz ) and the half-life. Only
terminal phases showing good linearity (adjusted R2
> 0.7) were used for slope calculation. The estimated
half-life was compared with previously reported adduct
half-life20 by the Student t test. The potential covariates
affecting the adduct half-life were evaluated by Spearman’s rank correlation test for continuous variables
(age, body weight, and BMI z score) and 1-way analysis
of variance for categorical variables (sex, race, surgery,
and primary admission diagnosis).
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Figure 1. Profile of APAP protein adduct concentrations for all patients (top right: adducts on a semilog scale). Colors in line represent the individual
patients.

Results
Exploratory Data Analysis
A total of 1034 adduct measurements were obtained
from 181 research patients. Accordingly, a total of 1034
cumulative doses and 1034 mean doses were computed.
The demographic characteristics of the pediatric patients are summarized in Table 1. APAP formulations
administered consisted of injections (6.9%), suppositories (15.3%), elixirs (16.6%), solutions (28.2%), and
tablets (32.3%), with 35.2% of patients having received
more than 1 formulation. In addition, 29% of the
patients received either opioid (hydrocodone, codeine,
or oxycodone)- or diphenhydramine-containing formulations. The number of available blood samples
per patient ranged from 1 to 26, and most of the
patients (73%) had 2-7 samples obtained (Table 2).
Transaminase concentrations were available for 174 of
the 181 patients. Among the 174 patients, 112 patients
had both AST and ALT measurements, whereas the
remaining patients had only ALT measurements. None
of the patients had renal insufficiency or reported
taking alcohol or isoniazid, which have the potential
to interact with APAP hepatic metabolism through
CYP2E1 pathway.27,28
The adduct concentration varied widely across patients spanning a full order of magnitude (Figure 1).
However, 98% of adduct concentrations (1012 of 1034)
were below the previously determined toxicity cut point
of 1.0 nmol/mL.20,21 High adduct concentrations were
noted in 3 of 181 patients (2%), and these 3 patients are
discussed further in the following section of individual

patient analysis. For correlation analysis, the highest
strength of association (R2 = 0.31) was found between
the natural log-transformed cumulative doses (mg/kg)
and natural log-transformed adduct concentrations,
which was followed by a marginal correlation (R2 =
0.04) between the mean APAP dose (mg/kg) and the
adduct concentration. The AST and ALT values were
low or modestly elevated (<1000 IU/L) for the majority
of the patients (99.5%) with 19-182 IU/L (5%-95%
percentiles) and 9-163 IU/L(5%-95% percentiles) for
AST and ALT, respectively. Only 1 patient showed AST
and ALT levels greater than 1000 IU/L.
Linear Regression Analysis
Figure 2 depicts the regression line describing the
positive and linear relationship between the logtransformed cumulative dose and log-transformed
adduct concentration. This analysis covered 96% of the
available adduct concentrations, as the remaining ones
were beyond 48 hours after the most recent dose. The
slope of the base model was estimated to be 0.75 ±
0.04 (P < .001, mean ± SE), demonstrating a significant
increase in adduct concentrations as the cumulative
dose increases. The estimated R2 value indicated that
31% of the variability in adduct concentration could
be explained by cumulative dose. When this analysis was performed on the data (n = 68) excluding
patients who received APAP prior to admission, the
slope of regression and R2 showed minor disparity
(Supplemental Figure S1) from the model using the
entire cohort data, demonstrating that inclusion of the
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Figure 2. Linear regression of APAP protein adduct concentrations within 48 hours after the most recent dose. Solid line, regression line of adduct
concentrations against cumulative doses. Shaded area of regression line, 95% confidence interval for predicted adduct concentrations. Dotted line, cut
point of 1.0 nmol/mL for diagnosis of APAP toxicity. , random error.

preadmission APAP dosing data had minimal impact
on the results.
Multiple regression analysis and ANCOVA indicated that the addition of an admission diagnosis
improved the model fitting to a relatively large extent,
whereas age demonstrated only a mild effect on the
linear model (Supplemental Table S1). Variations in
slope and/or intercept were also observed as a function
of diagnosis and age. Consequently, we further evaluated the effect of diagnosis and age using stratified
data analysis (Figure 3). Patients admitted with suspected or presumed infection (n = 22) had remarkably
higher adduct concentrations than those observed for
patients admitted for noninfectious diseases (mean
concentrations, 0.35 vs 0.11 nmol/mL). The number
of sampling points (mean, 4.5 samples; median, 3.0
samples) for patients in this cohort did not show a
significant deviation from those (mean, 5.7 samples;
median, 4.0 samples) of the entire patient population.
The infection and noninfection groups had a similar
distribution of formulations as well. This observation
indicates that neither sampling schemes nor formulation contributed to the relationship between adduct
concentrations and infection. The subgroup of infants
showed a distinctive slope of 1.35, representing more
rapid elevation of adduct concentrations than other
age groups, whereas all adduct concentrations were far
below 1.0 nmol/mL for this subset. Compared with
children, adduct concentrations in adolescents were
more concentrated along the regression line, leading to

a stronger correlation (R2 = 0.41 vs 0.26) of adduct
levels with the cumulative doses. No sampling bias
was found in the stratified data by age group. The
most commonly used formulations (frequencies ࣙ 25%)
stratified by age were suppository (33%) for infants,
solution/elixir (48%) for children, and tablet (61%) for
adolescents.
Individual Patient Analysis
The clinical histories of 3 patients with adduct
concentration ࣙ 1.0 nmol/mL were reviewed and
are summarized as case reports in Supplemental
Table S2. There was no evidence that any comedication was associated with these abnormal adduct levels.
When adduct concentrations exceeded 1.0 nmol/mL, all
these patients had cumulative doses close to or greater
than 100 mg/kg. By comparison, the distribution of
hepatic transaminases and adduct levels for children
with cumulative doses greater than 100 mg/kg ranged
from 14 to 131 IU/L for AST, 7 to 214 IU/L for ALT,
and 0.02 to 2.1 nmol/mL for adducts.
A fourth patient received two APAP doses (15 mg/kg
per dose) in the 24 hours prior to cardiac surgery.
AST and ALT prior to surgery were 66 and 18 IU/L,
respectively. However, the patient developed cardiac
arrest after surgery, and AST and ALT rose to 3940 and
9741 IU/L, respectively. Because her adduct concentrations were all below 0.10 nmol/mL, the elevation of
transaminase was attributed to hepatic ischemia instead
of APAP dosing.
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Figure 3. Analysis of adduct concentrations stratified by age (A, B, C) and primary admission diagnosis (D, E). Red dots, adduct concentrations in
patients with suspected infection. Solid line, regression line of adduct concentrations against cumulative doses. Shaded area of regression line, 95%
confidence interval for predicted adduct concentrations.

Adduct Half-life Analysis
The adduct concentrations of 8 patients were used
to determine the adduct half-life because only these
patients had sufficient sampling points (n ࣙ 3) for calculation of the terminal slope (Figure 4). The half-life was
estimated to be 2.17 ± 1.04 days (mean ± standard deviation [SD]), ranging from 1.04 to 4.13 days. The large
variation in half-life limited the statistical power of
comparison; hence, we could not determine whether the
adduct half-life we observed after multiple therapeutic
doses was longer than the half-life (1.47 ± 0.30 days)29
reported for children after acute overdose. In addition,
no covariates were found to significantly affect the halflife (P > .05 for all tested covariates). The individual
half-life and associated demographic characteristics are
listed in Supplemental Table S3.

Discussion
To date, very few clinical studies have investigated
the potential toxicity of repeated therapeutic doses
of APAP administered to hospitalized children.7,30–32
The present study evaluated the relationships between
APAP doses, AST and ALT values, and APAP protein
adduct levels in 181 hospitalized children. Our data
demonstrate that APAP protein adduct levels can be

detected at low levels in hospitalized children receiving
therapeutic doses of APAP. Moreover, we found that
a relatively low percentage of hospitalized children
(2%) had adduct levels above the previously identified
toxicity cut point for adducts of 1.0 nmol/mL, a value
associated with ALT elevation >1000 IU/L in adults
following acute APAP overdose. Our findings
contribute to a body of literature evaluating the
relationships of adducts to transaminase values in
patients in different clinical settings.23,24,32 Although
98% of adduct concentrations were below 1.0 nmol/mL,
we observed a dose-dependent relationship for
APAP protein adducts, a finding previously noted in
experimental models of APAP toxicity.33–35 To our
knowledge, the present study is the first to observe
and quantify this relationship in the clinical setting
of APAP dosing in hospitalized children. It should
be noted that the present study was associated with
considerable variability because of varying disease
conditions, sampling times, APAP formulations, and
dosing frequency. To overcome such wide variability,
we applied log-transformation to the adduct data
aiming to capture the changes in the magnitude of
adduct concentrations given certain APAP doses. A
linear and positive relationship was found between

Jiang et al
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Figure 4. Analysis of adduct half-life. Black dots represent adduct concentrations after the last dose of APAP. #, Patient with ࣙ1.0 nmol/mL adduct
concentration. The case report of this patient is included in Supplemental Table S2.

the log-transformed cumulative dose and the logtransformed adduct concentrations, with an R2 of
0.31. Given the great diversity of the study patients (eg,
age, race, and admission diagnosis) and heterogeneity
of the dosing scenarios (eg, formulations and dosing
interval) in this observational study, this R2 value
demonstrates a fair correlation between the cumulative
APAP dose and adduct concentration.
Among clinical covariates, patients with suspected
infection had higher adduct concentrations than patients with other admission diagnoses. The reason for
this observation is unclear. A previous study, in which
mice with active adenoviral infection were treated with
APAP, found that mice were protected from APAP liver
injury and that the CYP2E1 activity was reduced.36
Multiple other mechanistic pathways have been implicated in APAP toxicity (eg, oxidative and/or nitrosative stress, mitochondrial injury) and may have
contributed to the findings that we observed in this
study. Moreover, infants showed a distinctive adduct
profile with rapid adduct elevation (Figure 3A), which
may be related to their unique physiological characteristics. Because of the limitation of this small cohort
(n = 11), we could not make further inference at this
stage. The higher correlation between the cumulative
APAP dose and adduct concentration in adolescents
(Figure 3C) is most likely associated with 2 factors:
(1) less diversity in formulations used in adolescents
as tablets accounted for more than half of the APAP
formulations and (2) the relative maturation of drug

metabolism pathways in adolescents compared with
children.
Other than the identified covariate effect, the remaining sources of variability can likely be attributed to
factors not directly investigated in the present study.
For instance, the liver abundance of CYP2E1 carries
considerable interindividual variability in humans, although CYP2E1 is considered to lack clinically relevant
polymorphisms. Various data sources have reported 4to 20-fold variation in CYP2E1 level per unit human
microsomal protein.37 In addition to the potential variability of adduct formation mediated by CYP2E1, the
observed adduct half-life in the current study was also
highly variable (RSD, 48%). This may have, in part,
contributed to the elevation of adduct levels following
repeated APAP dosing because the dosing intervals
(6 to 11 hours) were much shorter than the observed
adduct half-life (2.17 days). Another possibility contributing to the adduct elevation is the accumulation of
APAP following chronic dosing in children, as reported
by Nahata et al.30 However, other reports failed to
observe accumulation of APAP,38,39 and our study did
not include APAP measurements that are needed to
further explore this possibility.
The clinical implication of the above findings remains to be seen. The HPLC-EC assay has remarkable
sensitivity, with an LLOQ of 0.03 nmol/mL.19 Previous
data using time-course and dose-response designs in
experimental models of APAP toxicity have shown that
liver adducts and circulating adducts may be detected
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prior to ALT elevations.33–35 The exact mechanism of
adduct release from cells is still unknown. A recent
study examined whether adducts are released by extracellular vesicles, a known pathway for extracellular
cargo transport; it found no adducts in extracellular
vesicles.40 Although adducts have a strong correlation
with ALT values in patients with ALT > 1000 IU/L,
the correlative relationship was found to be weaker at
lower ALT concentrations in an earlier study,41 which
agreed with our findings. This observation may be
because of the variations in the mechanisms of adduct
and hepatic transaminase release, variation in assay
sensitivity between analytical laboratory methods, or
other factors.

Conclusions
APAP protein adduct levels obtained from a large
cohort of hospitalized children with various admitting
diagnoses who were receiving APAP were low and
not at levels previously associated with APAP-related
acute liver injury. Because patients with higher cumulative doses of APAP had higher adduct levels, careful
monitoring of the need for scheduled APAP versus
“as-needed” dosing appears prudent.
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